Personalized Therapeutic Strategies in Gastrointestinal Surgery

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 402

Special Issue Editor


E-Mail Website
Guest Editor
Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Ge-melli, Rome, Italy
Interests: surgical oncology; cytoreductive surgery; hipec; laparoscopic surgery; colorectal cancer; gastric cancer; peritoneal me-tastases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of gastrointestinal surgery is undergoing a transformative shift with the advent of personalized therapeutic strategies, particularly in the realm of oncologic surgery. As our understanding of the genetic and molecular underpinnings of gastrointestinal cancers deepens, the potential for tailored interventions that enhance surgical outcomes and patient quality of life is becoming increasingly apparent. This Special Issue is dedicated to exploring the cutting-edge advancements and clinical applications of personalized medicine in gastrointestinal oncologic surgery.

Personalized therapeutic strategies leverage patient-specific data, including genetic, epigenetic, and phenotypic information, to devise targeted surgical approaches and adjuvant treatments. These strategies promise to optimize oncologic control while minimizing adverse effects, thereby improving overall survival rates and postoperative recovery. Key areas of focus in this Special Issue include the integration of genomic profiling in surgical planning, the role of minimally invasive techniques and robotic surgery in personalized treatment, and the impact of novel biomarkers on predicting surgical outcomes.

By bringing together leading experts in the field, this Special Issue aims to provide a comprehensive overview of the current state of personalized therapeutic approaches in gastrointestinal oncologic surgery. Through original research articles and reviews, we hope to highlight the potential of personalized strategies to revolutionize surgical oncology and set the stage for future innovations that will continue to advance patient care.

Dr. Francesco Santullo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical oncology
  • cytoreductive surgery
  • laparoscopic surgery
  • colorectal surgery
  • gastric cancer
  • hipec
  • pipac
  • peritoneal metastases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 748 KiB  
Article
Evaluating the Long-Term Impact of Cytoreductive Surgery for Gastric Cancer with Peritoneal Metastasis: Are We on the Right Path?
by Cecilia Orsini, Matteo Aulicino, Giorgio D’Annibale, Marianna Cantelmo, Sara Totaro Aprile, Paolo Catania, Lorenzo Barberis, Federica Ferracci, Miriam Attalla El Halabieh, Carlo Abatini, Claudio Lodoli, Andrea Di Giorgio, Antonia Strippoli, Fabio Pacelli and Francesco Santullo
J. Pers. Med. 2025, 15(7), 300; https://doi.org/10.3390/jpm15070300 - 10 Jul 2025
Viewed by 203
Abstract
Background: Peritoneal metastases from gastric cancer (GCPM) represent a significant clinical challenge in terms of therapeutic options and prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated promising survival benefits within a multimodal approach, particularly in carefully selected patients. Methods: [...] Read more.
Background: Peritoneal metastases from gastric cancer (GCPM) represent a significant clinical challenge in terms of therapeutic options and prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated promising survival benefits within a multimodal approach, particularly in carefully selected patients. Methods: This retrospective single-center study evaluated outcomes in patients with synchronous GCPM treated with CRS + HIPEC following neoadjuvant chemotherapy. The primary endpoints included overall survival (OS), disease-free survival (DFS), and identification of prognostic factors associated with poor outcomes. Additionally, we sought to characterize patients achieving long-term survival (OS ≥ 24 months). Results: The median OS and DFS were 18 and 13 months, respectively. A peritoneal cancer index (PCI) ≥ 7 and major postoperative complications were independently associated with reduced survival. Recurrence was significantly linked to PCI ≥ 7 and signet ring cell histology. Stratification by survival outcome identified PCI ≥ 7 as the only statistically significant variable differentiating average- and long-survival groups. Moreover, elevated PCI was independently associated with a higher incidence of major postoperative complications. Conclusions: CRS + HIPEC may offer a survival advantage over the use of systemic therapy exclusively in appropriately selected patients, particularly those with limited peritoneal disease burden. These results underscore the importance of accurate patient selection to balance surgical risks and maximize oncological benefits in the treatment of GCPM. Full article
(This article belongs to the Special Issue Personalized Therapeutic Strategies in Gastrointestinal Surgery)
Show Figures

Figure 1

Back to TopTop